The Tremor Paradox: Parkinson’s Disease and the Dopamine Enigma

A clinical imaging investigation conducted in Finland suggests that rest tremor in Parkinson’s disease is not attributable to diminished dopamine levels. Conversely, tremor appears to correlate with comparatively better-preserved dopamine functionality.

Researchers affiliated with the University of Turku and Turku University Hospital in Finland undertook an analysis of clinical data alongside dopamine transporter (DAT) imaging results from 414 patients diagnosed in Finland. This patient group comprised individuals who had undergone examination within standard clinical protocols due to indeterminate parkinsonism or tremor, lending exceptional generalizability to the findings concerning real-world clinical scenarios. The outcomes of this research were disseminated on March 19, 2026, in the esteemed medical publication, Neurology^®, the official journal of the American Academy of Neurology.
The principal motor manifestations of Parkinson’s disease encompass bradykinesia (slowness of movement), rigidity (muscle stiffness), and rest tremor. It is well-established that bradykinesia and rigidity are indicative of the deterioration of dopamine-producing neurons. Given the contralateral nature of most neural pathways, this correlation is typically observed in the striatum on the side opposite to where the symptoms manifest. In stark contrast, the underlying biological mechanisms responsible for rest tremor have remained elusive for a considerable period.

This investigative study brought to light a distinct and reproducible pattern: rest tremor was demonstrably linked to elevated dopamine transporter binding within the striatum on the same side as the observed tremor. However, the other hallmark motor symptoms exhibited the anticipated inverse relationship with dopamine deficiencies in the contralateral hemisphere.

These findings indicate that more pronounced rest tremor does not simply signify advanced degradation of the dopaminergic system. Tremor appears to stem from a neurobiological mechanism that is partly independent.”

Kalle Niemi, MD, PhD, lead author, neurologist

The resultant data corroborate the research group’s prior findings, which were derived from an analysis of the international Parkinson’s Progression Markers Initiative (PPMI) cohort, utilizing a novel imaging analysis methodology initially developed by the research team. The successful replication of these results within an independent patient cohort, representative of clinical populations, significantly bolsters the credibility of the observed phenomenon.
“Our discoveries lend support to the hypothesis that diverse symptoms within Parkinson’s disease might be governed by distinct neural networks and distinct neurotransmitter-related mechanisms,” Dr. Niemi elaborated. “This perspective could elucidate why tremor exhibits a different behavioral pattern compared to symptoms such as bradykinesia.”
Employing the identical methodological framework, the research cadre also established that key non-motor symptoms commonly associated with Parkinson’s disease, including depression, anxiety, and REM sleep behavior disorder, are predominantly interconnected with monoaminergic systems that function independently of dopamine.
Collectively, these insights reinforce the understanding of Parkinson’s disease as a multifaceted neurological disorder characterized by alterations across a variety of neural networks and neurotransmitter systems.
A more granular comprehension of the biological distinctions among various symptoms could, moving forward, pave the way for the development of more precisely tailored and individualized therapeutic strategies.